<DOC>
	<DOCNO>NCT00001524</DOCNO>
	<brief_summary>This study test effectiveness topical thalidomide heal mouth sore HIV infect patient . Oral ( PO ) thalidomide heals sores dose 200 mg per day . However , PO thalidomide cause drowsiness , skin rash , allergic reaction , increase viral load , even nerve damage may reversible . This study evaluate efficacy topical formulation thalidomide ( place directly surface sore ) healing sore . Persons HIV infection acquire immunodeficiency least 18 year age one chronic , painful intraoral lesion may eligible study . Subjects must refer primary care physician manage care , must HIV/AIDS status confirm . Patients ' HIV treatment regimen alter receive highly active therapy exclude . Patients exclude concurrently treat mucosal lesion ( include topical systemic steroid , viscous lidocaine , topical systemic anti-fungals , mouthwash ) , concurrent thalidomide therapy ; receving chemotherapy radiation therapy neoplasm ; use concurrent acute therapy opportunistic infection ; concurrent use sedative ( CNS depressant alcohol use ) ; history allergy thalidomide ; pre-existing peripheral neuropathy grade II high ; pregnant lactating female practice contraception accord FDA guideline thalidomide .</brief_summary>
	<brief_title>Thalidomide Treat Oral Lesions HIV-Infected Patients</brief_title>
	<detailed_description>The propose clinical trial evaluate efficacy topically-applied thalidomide treatment painful oral lesion HIV-infected patient . Limited data suggest drug may effective give systemically , accompany high incidence side effect . Administration drug topically onto lesion result high local concentration within lesion thereby suppress tumor necrosis factor think related size severity lesion . Subjects randomly allocate one three possible group : systemic administration thalidomide , topical administration thalidomide , placebo . The dose thalidomide determine dose escalation pilot study prior main study . Healing , pain , incidence side effect assess baseline weekly eight week . Successful demonstration enhance therapeutic effect reduce toxicity may provide basis development novel route administration drug treatment painful oral lesion associate HIV infection disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Burning Mouth Syndrome</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>INCLUSION CRITERIA FOR PATIENTS : Persons HIV infection acquire immunodeficiency least 18 year age one chronic , painful intraoral lesion constitute study sample study . Subjects must refer primary care physician manage care , must HIV/AIDS status confirm current CD4 status provide primary physician . Patients ' HIV treatment regimen alter receive highly active antiretroviral therapy exclude . EXCLUSION CRITERIA FOR PATIENTS : Patients exclude participation take concurrent treatment mucosal lesion ( include topical systemic steroid , viscous lidocaine , topical systemic antifungal , mouthwash ) , prior concurrent thalidomide therapy , chemotherapy radiation therapy neoplasm , concurrent acute therapy opportunistic infection , concurrent use sedative ( CNS depressant alcohol use ) , history allergy thalidomide , preexist peripheral neuropathy grade II high , female childbearing potential . Pregnant lactating female exclude . INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS : Patients must age 40 60 year . EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS : Can use prescription nonprescription medication except birth control . Can acute chronic current infection illness . Can autoimmune condition , diabetes , lupus , HIV ( must healthy ) . Can use within 24 hour : antiinflammatory drug analgesic . Can use within 24 hour : antihistamine allergy medication . Can use within 3 week : antidepressant steroid .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>Thalidomide</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Delayed Healing</keyword>
	<keyword>Painful Oral Lesions</keyword>
	<keyword>HIV/AIDS</keyword>
	<keyword>Mouth Ulcers</keyword>
	<keyword>Aphthous Ulcers</keyword>
	<keyword>Healing</keyword>
	<keyword>Cytokines</keyword>
</DOC>